1 hour ago | Video
CNN’s The Situation Room discusses the current dispute over health care coverage for contraception. Will there be a contraception compromise?
|
Feb 8 | News
CAMBRIDGE, Mass. (AP) — Move over, coffee and Red Bull. A Harvard professor thinks the next big thing will be people inhaling their caffeine from a lipstick-sized tube. Critics say the novel product is not without its risks.
|
Feb 7 | News
WASHINGTON (AP) — The Obama administration wants to spend just over half a billion dollars on Alzheimer's research next year, hoping to battle back against what could become the defining disease of the aging baby-boom generation.
|
Feb 6 | Video
In a paper published in the journal "Nature", researchers from the University of California, San Francisco argue that sugar can lead to chronic diseases.
|
Feb 3 | News
WHITEHOUSE STATION, N.J. (AP) — Merck said Thursday it received U.S. approval for an extended-release version of its diabetes drug Janumet designed to be taken once a day, instead of twice a day.
|
Feb 2 | News
TACOMA, Wash. (AP) — A federal judge is considering whether Washington state can require pharmacies to stock and sell Plan B or other emergency contraceptives, even in the face of religious objections by druggists who believe they destroy human life.
|
Feb 2 | News
KARACHI, Pakistan (AP) — Pakistani authorities have closed a drug factory alleged to have made faulty heart medicine that killed over 100 patients.
|
Feb 2 | News
Mylan Inc. today announced that its subsidiary Mylan Laboratories Limited (formerly Matrix Laboratories Limited) has received tentative approval from the FDA for its Abbreviated New Drug Application (ANDA) for Atorvastatin Calcium Tablets, 10 mg (base), 20 mg (base), 40 mg (base) and 80 mg (base).
|
Feb 1 | News
Novartis announced today that following a priority review, the FDA has approved an update to the Gleevec (imatinib mesylate) tablets label to recommend 36 months of treatment after surgery for adult patients with KIT (CD117)-positive gastrointestinal stromal tumors (GIST) who met the risk of recurrence inclusion criteria of the pivotal trial.
|
Jan 30 | Blogs
Document management software enables investigators to present the information used to reach conclusions clearly and concisely and it helps reviewers to track and approve investigations.
|